873 related articles for article (PubMed ID: 26416327)
1. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
Xia Y; Stadler D; Lucifora J; Reisinger F; Webb D; Hösel M; Michler T; Wisskirchen K; Cheng X; Zhang K; Chou WM; Wettengel JM; Malo A; Bohne F; Hoffmann D; Eyer F; Thimme R; Falk CS; Thasler WE; Heikenwalder M; Protzer U
Gastroenterology; 2016 Jan; 150(1):194-205. PubMed ID: 26416327
[TBL] [Abstract][Full Text] [Related]
2. Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.
Shi H; Lu L; Zhang NP; Zhang SC; Shen XZ
World J Gastroenterol; 2012 Jul; 18(27):3617-22. PubMed ID: 22826629
[TBL] [Abstract][Full Text] [Related]
3. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
[TBL] [Abstract][Full Text] [Related]
4. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions.
Phillips S; Chokshi S; Riva A; Evans A; Williams R; Naoumov NV
J Immunol; 2010 Jan; 184(1):287-95. PubMed ID: 19949099
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
6. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes.
Bohne F; Chmielewski M; Ebert G; Wiegmann K; Kürschner T; Schulze A; Urban S; Krönke M; Abken H; Protzer U
Gastroenterology; 2008 Jan; 134(1):239-47. PubMed ID: 18166356
[TBL] [Abstract][Full Text] [Related]
7. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
[TBL] [Abstract][Full Text] [Related]
8. Suppression of hepatitis B virus replication in Tupaia hepatocytes by tumor necrosis factor alpha of Tupaia belangeri.
Xu Y; Köck J; Lu Y; Yang D; Lu M; Zhao X
Comp Immunol Microbiol Infect Dis; 2011 Jul; 34(4):361-8. PubMed ID: 21684599
[TBL] [Abstract][Full Text] [Related]
9. Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes.
Bockmann JH; Stadler D; Xia Y; Ko C; Wettengel JM; Schulze Zur Wiesch J; Dandri M; Protzer U
J Infect Dis; 2019 Jul; 220(4):567-577. PubMed ID: 30923817
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
[TBL] [Abstract][Full Text] [Related]
11. Cytokine inhibition of the hepatitis B virus core promoter.
Romero R; Lavine JE
Hepatology; 1996 Jan; 23(1):17-23. PubMed ID: 8550037
[TBL] [Abstract][Full Text] [Related]
12. Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p.
Faure-Dupuy S; Riedl T; Rolland M; Hizir Z; Reisinger F; Neuhaus K; Schuehle S; Remouchamps C; Gillet N; Schönung M; Stadler M; Wettengel J; Barnault R; Parent R; Schuster LC; Farhat R; Prokosch S; Leuchtenberger C; Öllinger R; Engleitner T; Rippe K; Rad R; Unger K; Tscharahganeh D; Lipka DB; Protzer U; Durantel D; Lucifora J; Dejardin E; Heikenwälder M
JHEP Rep; 2021 Dec; 3(6):100354. PubMed ID: 34704004
[TBL] [Abstract][Full Text] [Related]
13. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
14. Distribution of Hepatitis B Virus Nuclear DNA.
Li M; Sohn JA; Seeger C
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046450
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures.
Pasquetto V; Wieland SF; Uprichard SL; Tripodi M; Chisari FV
J Virol; 2002 Jun; 76(11):5646-53. PubMed ID: 11991993
[TBL] [Abstract][Full Text] [Related]
16. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation.
Zhang W; Chen J; Wu M; Zhang X; Zhang M; Yue L; Li Y; Liu J; Li B; Shen F; Wang Y; Bai L; Protzer U; Levrero M; Yuan Z
Hepatology; 2017 Aug; 66(2):398-415. PubMed ID: 28236308
[TBL] [Abstract][Full Text] [Related]
17. A Functional Variant in Ubiquitin Conjugating Enzyme E2 L3 Contributes to Hepatitis B Virus Infection and Maintains Covalently Closed Circular DNA Stability by Inducing Degradation of Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3A.
Zhou L; Ren JH; Cheng ST; Xu HM; Chen WX; Chen DP; Wong VKW; Law BYK; Liu Y; Cai XF; Tang H; Yu HB; Hu JL; Hu Y; Zhou HZ; Ren F; He L; Hu ZW; Jiang H; Xu HY; Huang AL; Chen J
Hepatology; 2019 May; 69(5):1885-1902. PubMed ID: 30614547
[TBL] [Abstract][Full Text] [Related]
18. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
[TBL] [Abstract][Full Text] [Related]
19. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice.
Lutgehetmann M; Volz T; Köpke A; Broja T; Tigges E; Lohse AW; Fuchs E; Murray JM; Petersen J; Dandri M
Hepatology; 2010 Jul; 52(1):16-24. PubMed ID: 20578126
[TBL] [Abstract][Full Text] [Related]
20. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
